These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3078182)

  • 1. [Results of the combined treatment of advanced multiple myeloma by the M-2 protocol: cyclophosphamide, vincristine, melphalan, nitrosourea and prednisone].
    Gola A; Niewolna M; Weryńska B
    Pol Arch Med Wewn; 1987 May; 77(5):200-5. PubMed ID: 3078182
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results with the use of the M-2 protocol in plasmacytoma].
    Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
    Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
    Hansen OP; Clausen NA; Drivsholm A; Laursen B
    Scand J Haematol; 1985 Nov; 35(5):518-24. PubMed ID: 3911373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
    Raya Sánchez JM; González Brito G; Marsá Vila L; Brito Barroso ML; Hernández Nieto L
    Sangre (Barc); 1991 Oct; 36(5):434-5. PubMed ID: 1816642
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pneumonia caused by Salmonella in a patient with myeloma].
    Fernández P; Roldán V; García MC; Gil MT; Rivas C
    Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
    [No Abstract]   [Full Text] [Related]  

  • 16. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 19. [The influence of verapamil on platelet function in patients with multiple myeloma].
    Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M
    Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute ischemia and heart failure during cyclic chemotherapy in a patient with plasmocytic myeloma].
    Drzewoski J; Olszańska-Skorek T; Urbańska-Ryś H; Kończalik P; Krykowski E
    Pol Tyg Lek; 1990 Dec 17-31; 45(51-52):1056-8. PubMed ID: 2098746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.